An open source and reduce expenditure ROS generation strategy for chemodynamic/photodynamic synergistic therapy.
Clicks: 319
ID: 106771
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
69.5
/100
319 views
234 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #99 of 485 articles by views in Nature communications
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 485 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The therapeutic effect of reactive oxygen species (ROS)-involved cancer therapies is significantly limited by shortage of oxy-substrates, such as hypoxia in photodynamic therapy (PDT) and insufficient hydrogen peroxide (HO) in chemodynamic therapy (CDT). Here, we report a HO/O self-supplying nanoagent, (MSNs@CaO-ICG)@LA, which consists of manganese silicate (MSN)-supported calcium peroxide (CaO) and indocyanine green (ICG) with further surface modification of phase-change material lauric acid (LA). Under laser irradiation, ICG simultaneously generates singlet oxygen and emits heat to melt the LA. The exposed CaO reacts with water to produce O and HO for hypoxia-relieved ICG-mediated PDT and HO-supplying MSN-based CDT, acting as an open source strategy for ROS production. Additionally, the MSNs-induced glutathione depletion protects ROS from scavenging, termed reduce expenditure. This open source and reduce expenditure strategy is effective in inhibiting tumor growth both in vitro and in vivo, and significantly improves ROS generation efficiency from multi-level for ROS-involved cancer therapies.
| Reference Key |
liu2020annature
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Liu, Conghui;Cao, Yu;Cheng, Yaru;Wang, Dongdong;Xu, Tailin;Su, Lei;Zhang, Xueji;Dong, Haifeng; |
| Journal | Nature communications |
| Year | 2020 |
| DOI |
10.1038/s41467-020-15591-4
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.